R

Rigel Pharmaceuticals
D

RIGL

16.540
USD
-0.51
(-2.99%)
مفتوح الان
حجم التداول
895
الربح لكل سهم
0
العائد الربحي
-
P/E
61
حجم السوق
291,352,762
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    -2.09
    (-0.79%)
    261.46 USD
    BMY
    BMY
    -0.300
    (-0.52%)
    56.980 USD
    GILD
    GILD
    0.100
    (0.11%)
    92.670 USD
    I
    INCY
    0.390
    (0.57%)
    69.300 USD
    LLY
    LLY
    11.09
    (1.44%)
    780.71 USD
    MRK
    MRK
    0.250
    (0.25%)
    98.660 USD
    PFE
    PFE
    0.005
    (0.02%)
    26.365 USD
    REGN
    REGN
    8.80
    (1.25%)
    711.40 USD
    المزيد
الأخبار
المقالات

العنوان: Rigel Pharmaceuticals Inc

القطاع: Healthcare
الصناعة: Biotechnology
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.